Conformational analysis of site-specific DNA cross-links of cisplatin-distamycin conjugates.
The requirement for novel platinum antitumor drugs led to the concept of synthesis of novel platinum drugs based on targeting cisplatin to various carrier molecules. We have shown [Loskotova, H., and Brabec, V. (1999) Eur. J. Biochem. 266, 392-402] that attachment of DNA minor-groove-binder distamycin to cisplatin changes several features of DNA-binding mode of the parent platinum drug. Major differences comprise different conformational changes in DNA and a considerably higher interstrand cross-linking efficiency. The studies of the present work have been directed to the analysis of oligodeoxyribonucleotide duplexes containing single, site-specific adducts of platinum-distamycin conjugates. These uniquely modified duplexes were analyzed by Maxam-Gilbert footprinting, phase-sensitive gel electrophoresis bending assay and chemical probes of DNA conformation. The results have indicated that the attachment of distamycin to cisplatin mainly affects the sites involved in the interstrand cross-links so that these adducts are preferentially formed between complementary guanine and cytosine residues. This interstrand cross-link bends the helix axis by approximately 35 degrees toward minor groove, unwinds DNA by approximately 95 degrees and distorts DNA symmetrically around the adduct. In addition, CD spectra of restriction fragments modified by the cisplatin-distamycin conjugates have demonstrated that distamycin moiety in the interstrand cross-links of these compounds interacts with DNA. This interaction facilitates the formation of these adducts. Hence, the structural impact of the specific interstrand cross-link detected in this study deserves attention when biological behavior of cisplatin derivatives targeted by oligopeptide DNA minor-groove-binders is evaluated.
Kostrhunova
H
H
Institute of Biophysics, Academy of Sciences of the Czech Republic, CZ-61265 Brno, Czech Republic.
Brabec
V
V
D001966:Bromine / Q000737:chemistry; D002942:Circular Dichroism; D002945:Cisplatin / Q000737:chemistry*; D003432:Cross-Linking Reagents / Q000737:chemistry*; D004247:DNA / Q000737:chemistry*; D018736:DNA Adducts / Q000737:chemistry*; D004277:DNA, Single-Stranded / Q000737:chemistry; D004047:Diethyl Pyrocarbonate / Q000737:chemistry; D015226:Dinucleoside Phosphates / Q000737:chemistry*; D004214:Distamycins / Q000737:chemistry*; D009690:Nucleic Acid Conformation; D009692:Nucleic Acid Heteroduplexes / Q000138:chemical synthesis / Q000737:chemistry; D009838:Oligodeoxyribonucleotides / Q000138:chemical synthesis / Q000737:chemistry; D011196:Potassium Permanganate / Q000737:chemistry; D011742:Pyrimidine Nucleotides / Q000138:chemical synthesis / Q000737:chemistry
D003432:Cross-Linking Reagents; D018736:DNA Adducts; D004277:DNA, Single-Stranded; D015226:Dinucleoside Phosphates; D004214:Distamycins; D009692:Nucleic Acid Heteroduplexes; D009838:Oligodeoxyribonucleotides; D011742:Pyrimidine Nucleotides; C057270:cisplatin-DNA adduct; C094059:cisplatin-deoxy(guanosine monophosphate guanosine) adduct; D011196:Potassium Permanganate; C034298:deoxyguanylyl-(3'-5')-guanosine; C030000:stallimycin; D004247:DNA; D004047:Diethyl Pyrocarbonate; D002945:Cisplatin; D001966:Bromine